Business Wire

Nomad Foods Urges Food Industry to Adopt End-to-End Carbon Impact Product Assessment to Help Tackle the Climate Emergency

Share

Nomad Foods, Europe’s leading frozen food company, which owns brands including Birds Eye, Findus and iglo, is calling on the food industry and regulators across Europe to consider a more comprehensive, end-to-end approach to Life Cycle Assessment (LCA) studies, which includes food loss and waste impacts, to improve transparency for consumers and drive critical action to reduce carbon emissions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005425/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Results for the 22 frozen products assessed under the new study showed that most had an equal or lower carbon footprint than similar products using other preservation methods (Graphic: Business Wire)

Food production is a major contributor to climate change and making better environmental choices about what we eat and how we reduce food waste is one way for businesses and consumers to lower their carbon impact. To support this action, it’s vital that food companies fully understand their products’ total emissions footprint and provide clear, accurate and complete information.

With carbon labels and previous LCA studies on food often limited in scope, Nomad Foods has recently enlisted the help of international experts in impact assessments, PRé Sustainability, to conduct a unique end-to-end LCA study for 22 of Nomad Foods’ most popular products1.

Crucially, the study went beyond the scope of existing LCAs to include all stages of the product life cycle, incorporating new data on retailer and consumer food waste (an important element of Scope 3 emissions for food manufacturers) and primary data for all processing steps, improving the accuracy of the assessment – with the results peer reviewed by leading experts.

The study showed that retail and consumer food loss and waste – data which is not generally included in previous LCA assessments of food – plays an important part of the product life cycle and has a significant effect on a product’s overall environmental impact. In fact, retail and consumer food waste equates to an estimated 160m tonnes and 17.25m tonnes of CO2 in the EU and UK respectively2.

This new assessment means that, for the first time ever, clear conclusions can be drawn about the carbon footprint of frozen foods products and meaningful comparisons made to their non-frozen alternatives, while accounting for all relevant and material impacts. Results for the 22 frozen products assessed under the new study showed that most had an equal or lower carbon footprint than similar products using other preservation methods.

Stéfan Descheemaeker, Chief Executive Officer, Nomad Foods, said: “Consumer demand for nutritious, high-quality, sustainable food is growing and we believe it’s vital that we find ways to provide consumers with information that helps them make informed choices and provides confidence that sustainability claims are robust and evidence-based. To support this, we encourage the food industry, retailers and regulators to adopt a wider scope for LCAs as standard, taking the whole product life cycle into account. Based on the ground-breaking work that our teams have undertaken with life cycle experts PRé Sustainability, we can see there are significant benefits to frozen food in terms of longer-term food preservation and reduced food waste.”

Ellen Meijer, Consultant, PRé Sustainability, said: “This is one of the most elaborate frozen food LCA studies ever done, covering not only a wide range of frozen food products and their alternatives, but also approaching them all in a consistent methodological manner. Combined with the large amount of primary production data included and the attention to detail at each stage, this study is one of a kind. Based on this study, we are now in the unique position to draw conclusions about the carbon footprint of frozen food products compared to their non-frozen alternatives and generalize these conclusions across the frozen food category."

About Nomad Foods
Nomad Foods (NYSE: NOMD) is Europe’s leading frozen food company. The company's portfolio of iconic brands, which includes Birds Eye, Findus, iglo, Ledo and Frikom, have been a part of consumers' meals for generations, standing for great tasting food that is convenient, high quality and nutritious. Nomad Foods is headquartered in the United Kingdom. Additional information may be found at www.nomadfoods.com.

About PRé Sustainability
For thirty years PRé Sustainability has been at the forefront of life cycle thinking and has built on its knowledge and experience in sustainability metrics and impact assessments to provide state of the art methods, consulting services and software tools. Internationally, leading organizations work with PRé to integrate sustainability into their product development procedures in order to create business growth and business value. PRé has an office in the Netherlands and a global partner network to support large international or multi-client projects. www.pre-sustainability.com.

Notes to Editors:

1The comprehensive LCA study covered 10 keys stages. Stages 6 – 10 are the extended scope of the assessment not generally included in other studies:

  1. Ingredients: Production, including transport to factory.
  2. Processing: All activities that happen at the factory including energy, on-site waste and the treatment of it, and activities related to packaging the product. Also includes any pre-blanching or pre-freezing before it reaches the factory. The study included primary data for all material processes improving the accuracy of the assessment.
  3. Packaging: Packaging materials, including their transport to the factory.
  4. Distribution: Transport from the factory, storage at the distribution centre, transport to the retail hub and storage at the retail hub.
  5. Retail storage: Electricity and coolant use in the retail cold room and on the retail floor.
  6. Retail waste: Waste treatment of transport packaging, product losses and waste treatment of product losses, including processing, packaging and distribution of the product losses.
  7. Consumer transport: From the retailer to the consumer.
  8. Consumer storage: Electricity use for storage at the consumer.
  9. Consumer preparation: Energy use at the consumer to cook the food product, as well as any capital goods.
  10. Consumer waste: Waste treatment of primary packaging and product losses. This includes all upstream processes required to compensate for the product losses at the consumer.

26.9m tonnes of the UK’s annual total of 9.5m tonnes of food waste is down to the retailer and consumer, equivalent to 17.25m tonnes of CO2 (WRAP). In the EU the retail and consumer proportion of the 88m tonnes of food waste generated, equates to 160m tonnes of CO2. Calculation based on 1 kg of food waste creates 2.5 kg of CO22013; Food Wastage Footprint Impact on Natural Resources; United Nation’s Food & Agriculture Organization

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nomad Foods Media Contacts:
Sam Fulton
Group Director of Corporate Affairs
sam.fulton@nomadfoods.com
+44 7936 924691

Oliver Thomas
Corporate Affairs Manager
oliver.thomas@nomadfoods.com
+44 7568 108744

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

HiddenA line styled icon from Orion Icon Library.Eye